Mannkind CORP (MNKD) Institutional Ownership Tracker (Q2 2026)

On August 21, 2026, MannKind Corporation filed a prospectus supplement with the SEC under its previously established automatic shelf registration on Form S-3, setting up to issue and sell shares of common stock. The 8-K itself is largely routine paperwork — its main purpose is to attach a legal opinion from the law firm Cooley LLP confirming that the shares being offered are legally valid. The filing doesn't say how many shares are involved, at what price, or what the proceeds would be used for, so those details remain unclear.

MannKind (MNKD) filed an 8-K on August 5, 2026, to report its latest operating results. The filing says the company put out a press release covering the numbers, attached as Exhibit 99.1. No actual financial figures appear in this excerpt — they're all in that press release.

MannKind Corp entered a private placement with institutional investors, selling roughly 10.44 million shares at $3.89 each and pre-funded warrants for about 2.41 million shares at $3.88 per warrant share, raising approximately $50 million in gross proceeds. The company plans to use the net proceeds for general corporate purposes, including funding a $45 million contingent value rights payment triggered by FDA approval of Furoscix ReadyFlow.